Reviewers: YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers: YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
Citation:
|
Reviewers: YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers: YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
|
Reviewers: YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers: YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
Citation:
|
Reviewers: YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers: YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006
|